Ayrton Capital LLC has recently filed a Schedule 13G, revealing its ownership of 9.99% of Glucotrack, Inc. This filing is significant as it showcases Ayrton's growing influence in the medical instruments sector, particularly within the surgical and medical instruments and apparatus industry.

Background

Ayrton Capital LLC, incorporated in Delaware, is an investment management firm. The company has been active in filing reports with the SEC, including multiple Schedule 13G forms. Glucotrack, Inc., the subject of this filing, operates within the surgical and medical instruments and apparatus industry, according to its Standard Industrial Classification (SIC) code.

What the Filing Says

The recent filing, dated November 12, 2026, indicates that Ayrton Capital LLC beneficially owns 94,271 shares of Glucotrack, Inc., representing 9.99% of the company's outstanding shares as of September 30, 2026. The filing also mentions that these shares are subject to a 9.99% beneficial ownership blocker.

Impact

This disclosure may affect various stakeholders, including existing shareholders of Glucotrack, Inc., as Ayrton Capital's increased stake could influence company decisions and strategies. Competitors in the surgical and medical instruments sector may also need to evaluate their market positions in light of Ayrton's growing involvement.

What's Next

The filing does not say what happens next.